KTLA

Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America

Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...

Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...
KTLA

Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT ...

Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts Vector improvements demonstrate broad potential of Replicate's srRNA for ...
WKRN-TV

Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2

The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines The Company is exploring the use of the c-srRNA platform for the development of ...
KXAN

Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes

Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...